Skylands Capital LLC Has $663,000 Stake in Exact Sciences Co. (NASDAQ:EXAS)

Skylands Capital LLC lifted its stake in Exact Sciences Co. (NASDAQ:EXAS) by 2,850.0% in the fourth quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor owned 11,800 shares of the medical research company’s stock after purchasing an additional 11,400 shares during the period. Skylands Capital LLC’s holdings in Exact Sciences were worth $663,000 at the end of the most recent quarter.

Other institutional investors have also recently bought and sold shares of the company. Geode Capital Management LLC grew its holdings in Exact Sciences by 0.3% during the 3rd quarter. Geode Capital Management LLC now owns 3,105,970 shares of the medical research company’s stock worth $211,104,000 after acquiring an additional 7,873 shares during the period. Champlain Investment Partners LLC grew its position in shares of Exact Sciences by 10.9% during the 3rd quarter. Champlain Investment Partners LLC now owns 2,494,480 shares of the medical research company’s stock worth $169,924,000 after buying an additional 245,980 shares during the period. Bellevue Group AG increased its stake in shares of Exact Sciences by 25.1% in the 3rd quarter. Bellevue Group AG now owns 1,449,465 shares of the medical research company’s stock valued at $98,738,000 after acquiring an additional 290,585 shares during the last quarter. Charles Schwab Investment Management Inc. raised its position in shares of Exact Sciences by 3.6% in the 3rd quarter. Charles Schwab Investment Management Inc. now owns 1,292,090 shares of the medical research company’s stock valued at $88,017,000 after acquiring an additional 45,015 shares during the period. Finally, Groupama Asset Managment bought a new position in Exact Sciences during the 3rd quarter worth approximately $821,000. Institutional investors own 88.82% of the company’s stock.

Wall Street Analyst Weigh In

EXAS has been the topic of a number of recent analyst reports. Stifel Nicolaus reduced their price target on shares of Exact Sciences from $82.00 to $67.00 and set a “buy” rating on the stock in a research report on Wednesday, November 6th. Sanford C. Bernstein boosted their target price on Exact Sciences from $75.00 to $90.00 and gave the company an “outperform” rating in a research note on Wednesday, October 30th. Piper Sandler lowered their target price on Exact Sciences from $85.00 to $75.00 and set an “overweight” rating for the company in a research note on Monday, November 11th. Citigroup cut their price target on shares of Exact Sciences from $80.00 to $75.00 and set a “buy” rating on the stock in a research note on Wednesday, November 6th. Finally, Barclays lowered their price objective on shares of Exact Sciences from $70.00 to $65.00 and set an “overweight” rating for the company in a research report on Thursday. One analyst has rated the stock with a hold rating and eighteen have issued a buy rating to the company’s stock. According to data from MarketBeat, Exact Sciences presently has an average rating of “Moderate Buy” and an average price target of $72.06.

Exact Sciences Trading Down 0.5 %

Shares of EXAS stock opened at $49.26 on Monday. The company has a market cap of $9.15 billion, a PE ratio of -8.84 and a beta of 1.24. The company has a debt-to-equity ratio of 0.97, a quick ratio of 1.93 and a current ratio of 2.15. Exact Sciences Co. has a fifty-two week low of $40.62 and a fifty-two week high of $79.62. The stock’s fifty day moving average price is $54.91 and its two-hundred day moving average price is $60.04.

Exact Sciences (NASDAQ:EXAS) last issued its quarterly earnings data on Wednesday, February 19th. The medical research company reported ($0.06) earnings per share for the quarter, topping the consensus estimate of ($0.29) by $0.23. The company had revenue of $713.42 million for the quarter, compared to analysts’ expectations of $701.45 million. Exact Sciences had a negative net margin of 37.29% and a negative return on equity of 5.29%. Equities analysts predict that Exact Sciences Co. will post -0.58 EPS for the current fiscal year.

Exact Sciences Company Profile

Exact Sciences Corporation provides cancer screening and diagnostic test products in the United States and internationally. The company offers Cologuard, a non-invasive stool-based DNA screening test to detect DNA and hemoglobin biomarkers associated with colorectal cancer and pre-cancer. It also provides Oncotype DX Breast Recurrence Score Test; Oncotype DX Breast DCIS Score Test; Oncotype DX Colon Recurrence Score Test; OncoExTra Test for tumor profiling for patients with advanced, metastatic, refractory, relapsed, or recurrent cancer; and Covid-19 testing services.